The Future of Mental Health
Event Date: September 16 to 17, 2022
Over the last few years, the field of mental health has garnered the most investments relative to other clinical areas. This program brings together clinicians, scientists, entrepreneurs, and investors to understand what mental health care can and should look like in the next 2 decades. By all accounts, current systems of care do not serve patients and their families well: care is hard to access, inefficient and costly, and sometimes unable to restore function and quality of life. At the same time, from neuroimaging to artificial intelligence to mobile apps, we are bombarded with excitement about the future might bring. How do we get past the hype to envision better care? A key first step is understanding what the future could look like, and what would need to happen to make it a reality.
Available IN-PERSON or VIRTUAL
KEYNOTE SPEAKER
COURSE DIRECTORS
Roy H. Perlis, MD, MSc
Professor of Psychiatry, HMS
Director, Center for Experimental Drugs and Diagnostics, MGH
David Mou, MD, MBA
Director, MGH Psychiatry’s Innovation Council
Chief Executive Officer, Cerebral
SPEAKERS
| Cristina Cusin, MD Director, Ketamine Clinic and Associate Director, Depression Clinical and Research Program Massachusetts General Hospital Associate Professor of Psychiatry Harvard Medical School |
| Dr. Errol B. De Souza Executive Chairman Bionomics Ltd. |
| John Dunlop, PhD Head of Research and Development Neumora Therapeutics |
| Amit Etkin Founder and CEO Alto Neuroscience |
| Seth D. Feuerstein, MD, JD Faculty, Yale School of Medicine Founder and CEO, Oui Therapeutics Founder, Board Chair, Vytyl Health Senior Advisor, Athyrium Capital HQE, Department of Defense |
|
Marzyeh Ghassemi, PhD |
| George J. Goldsmith Chairman, CEO and Co-Founder, COMPASS Pathways PLC |
| Faith Gunning, Ph.D. Associate Professor of Psychology in Psychiatry Director of the Weill Cornell Institute of Geriatric Psychiatry Vice Chair for Research Department of Psychiatry |
| Peter Hames Co-Founder and President Big Health |
| Andy Keller, PhD President and CEO Linda Perryman Evans Presidential Chair Meadows Mental Health Policy Institute |
| Roger Kitterman Vice President Mass General Brigham Ventures |
|
Emily Lattie, PhD |
| Neil Leibowitz, MD, JD CMO Beacon Health Options |
| Carl D. Marci, MD Assistant Professor of Psychiatry, Harvard Medical School (part-time) Staff Clinician, MGH Revere Mental Health Center (part-time) Chief Psychiatrist and Managing Director, Mental Health and Neuroscience, OM1, Inc. |
| W. Eddie Martucci, PhD CEO and Co-Founder, Akili |
| Corey M. McCann, MD, PhD President and CEO, Pear Therapeutics, Inc |
| Doug Nemecek, MD, MBA Chief Medical Officer Evernorth Behavioral Health |
| Christopher M. Palmer, MD Director, Dept. of Postgraduate and Continuing Education, McLean Hospital Assistant Professor of Psychiatry, Harvard Medical School |
| Steven M. Paul, MD CEO and Chairman Karuna Therapeutics Professor of Psychiatry and Neurology Washington University School of Medicine |
| Guiseppe Raviola, MD, MPH Massachusetts General Hospital Department of Psychiatry Associate Director, The Chester M. Pierce, MD Global Psychiatry Division Assistant Professor of Psychiatry Division of Child and Adolescent Psychiatry Harvard Medical School Department of Global Health and Social Medicine Director, The Program in Global Mental Health and Social Change Assistant Professor in Global Health and Social Medicine |
| Jerrold Rosenbaum, MD Psychiatrist-in-Chief, Emeritus Director, Center for the Neuroscience of Psychedelics Massachusetts General Hospital Stanley Cobb Professor of Psychiatry Harvard Medical School |
| Mark Rus Chief Executive Officer Delix Therapeutics |
| Stephen Smith Cofounder and CEO of NOCD |
|
Anthony Sossong, MD |
|
Andrew Welchman, PhD |
|
Sabine Wilhelm, PhD |
| Zayed Yasin, MD, MBA SVP, Clinical |
